Faron Pharmaceuticals Ltd is a Finland-incorporated clinical-stage biopharmaceutical company focused on immunotherapy and oncology-related programs. Its shares trade on AIM and Nasdaq First North.
Faron Pharmaceuticals announces acceptance of bexmarilimab Phase I/II data for poster presentation at BSH 2026, while launching a new Phase II BEAM-X study evaluating the drug in AML patients post-stem cell transplantation.
Faron Pharmaceuticals announces Phase II BEAM-X trial evaluating bexmarilimab plus azacitidine in MRD-positive AML patients after stem cell transplantation. The Nordic AML Group-led trial will enroll 24 patients with first results expected 12-15 months after enrollment begins in Q3 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07460986 |
A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT05936229 |
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy |
WITHDRAWN | PHASE1/PHASE2 |
| NCT05428969 |
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT05171062 |
Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer |
WITHDRAWN | PHASE1 |
| NCT05104905 |
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma |
WITHDRAWN | PHASE1/PHASE2 |
| NCT04860518 |
Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19 |
TERMINATED | PHASE2 |
| NCT03733990 |
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) |
COMPLETED | PHASE1/PHASE2 |
| NCT03119701 |
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA |
TERMINATED | PHASE2 |
| NCT02622724 |
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS) |
TERMINATED | PHASE3 |
| NCT00789685 |
Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II |
COMPLETED | PHASE1/PHASE2 |
